Cerebral amyloid angiopathy (CAA) maintains a reservoir of vascular amyloid that continues to drive tau pathology even after parenchymal amyloid clearance. CSF p-tau217 may not fully normalize in patients with CAA, meaning p-tau217-based cessation thresholds require composite criteria incorporating CAA biomarkers (CAA-lobular microbleeds, vessel wall imaging) to prevent premature cessation. APOE ε4 carriers show delayed p-tau217 normalization due to enhanced vascular amyloid deposition that resists anti-Aβ antibody penetration.
Curated pathway from expert analysis
flowchart TD
A["APOE<br/>Apolipoprotein E"]
B["CLU (Clusterin)<br/> chaperone"]
C["Vascular Amyloid<br/>Deposit"]
D["Residual Amyloid<br/>Clearance Blocked"]
E["Perivascular<br/>Inflammation"]
F["CSF Biomarker<br/>Normalization Impaired"]
G["Cognitive<br/>Recovery Blocked"]
A --> C
B --> C
C --> D
D --> E
E --> F
F --> G
style A fill:#6a1b9a,stroke:#ce93d8,color:#ce93d8
style B fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9aNo linked papers recorded for this hypothesis yet.
Median TPM across 13 brain regions for APOE, CLU from GTEx v10.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for APOE, CLU.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No resource usage or linked notebooks recorded for this hypothesis yet.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF APOE ε4 homozygous carriers versus APOE ε4-negative carriers receive anti-Aβ antibody monotherapy for 24 months, THEN ε4/ε4 carriers will show delayed and attenuated CSF p-tau217 normalization (tro | Time to CSF p-tau217 nadir: APOE ε4/ε4 carriers ≥ 24 months; APOE ε4-negative carriers ≤ 12 months; final normalized p-tau217 in ε4/ε4 carriers remains 20-40% a | — no observation — | pending | 0.58 |
| IF patients with baseline CAA biomarkers (≥2 lobular microbleeds on SWI-MRI or positive vessel wall imaging) versus patients without CAA biomarkers receive anti-Aβ antibody therapy (lecanemab or donan | Mean CSF p-tau217 percent change from baseline at month 18: CAA+ < 30% reduction; CAA− > 50% reduction; between-group difference > 20 percentage points (p < 0.0 | — no observation — | pending | 0.65 |